Gilead Reports Phase 3 Data for Brigatinib in Ulcerative colitis

Gilead today announced Phase 3 results for brigatinib in patients with ulcerative colitis. The study demonstrated that brigatinib achieves complete response compared to standard of care or placebo. These results provide important insights into the treatment of ulcerative colitis and support the continued development of brigatinib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.